NZ292017A - Use of raloxifene to treat endometrial cancer - Google Patents

Use of raloxifene to treat endometrial cancer

Info

Publication number
NZ292017A
NZ292017A NZ292017A NZ29201795A NZ292017A NZ 292017 A NZ292017 A NZ 292017A NZ 292017 A NZ292017 A NZ 292017A NZ 29201795 A NZ29201795 A NZ 29201795A NZ 292017 A NZ292017 A NZ 292017A
Authority
NZ
New Zealand
Prior art keywords
placebo
raloxifene
compound
endometrial cancer
endometrial
Prior art date
Application number
NZ292017A
Other languages
English (en)
Inventor
Susan Margaret Boss
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ292017A publication Critical patent/NZ292017A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NZ292017A 1994-08-22 1995-08-21 Use of raloxifene to treat endometrial cancer NZ292017A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29385394A 1994-08-22 1994-08-22

Publications (1)

Publication Number Publication Date
NZ292017A true NZ292017A (en) 2000-07-28

Family

ID=23130867

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ292017A NZ292017A (en) 1994-08-22 1995-08-21 Use of raloxifene to treat endometrial cancer

Country Status (17)

Country Link
EP (1) EP0777476A4 (fi)
JP (1) JPH10504824A (fi)
KR (1) KR970705387A (fi)
AU (1) AU688112B2 (fi)
CA (1) CA2198119A1 (fi)
CZ (1) CZ51897A3 (fi)
FI (1) FI970717A (fi)
HU (1) HUT76890A (fi)
IL (1) IL115022A (fi)
MX (1) MX9701327A (fi)
MY (1) MY113757A (fi)
NO (1) NO970783L (fi)
NZ (1) NZ292017A (fi)
RU (1) RU2161964C2 (fi)
TW (1) TW404834B (fi)
WO (1) WO1996005833A1 (fi)
ZA (1) ZA956994B (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN115825414B (zh) * 2023-01-09 2023-04-25 中国医学科学院北京协和医院 血液或尿液代谢标志物及其在子宫内膜癌早筛中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
CA2160135A1 (en) * 1993-04-07 1994-10-13 Donald P. Mcdonnell Method for screening for receptor agonists
KR950010891A (ko) * 1993-10-15 1995-05-15 피터 지. 스트링거 내성 종양을 치료하는 방법
ZA956988B (en) * 1994-08-22 1997-02-21 Lilly Co Eli Methods of inhibiting primary endometrial hyperplasia.
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Also Published As

Publication number Publication date
RU2161964C2 (ru) 2001-01-20
TW404834B (en) 2000-09-11
WO1996005833A1 (en) 1996-02-29
FI970717A0 (fi) 1997-02-20
MY113757A (en) 2002-05-31
HUT76890A (en) 1997-12-29
AU3370095A (en) 1996-03-14
IL115022A0 (en) 1998-06-15
JPH10504824A (ja) 1998-05-12
KR970705387A (ko) 1997-10-09
CZ51897A3 (en) 1997-06-11
EP0777476A4 (en) 1999-06-23
MX9701327A (es) 1997-05-31
EP0777476A1 (en) 1997-06-11
ZA956994B (en) 1997-02-21
IL115022A (en) 2000-07-31
NO970783D0 (no) 1997-02-20
NO970783L (no) 1997-02-20
FI970717A (fi) 1997-02-20
AU688112B2 (en) 1998-03-05
CA2198119A1 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
JPH07215858A (ja) 機能障害性子宮出血を抑制する方法
US6303634B1 (en) Methods of preventing breast cancer
AU701701B2 (en) Methods of inhibiting breast disorders
AU688112B2 (en) Methods of inhibiting endometrial cancer
US5843964A (en) Methods of inhibiting endometrial mitoses
MXPA97002148A (en) Methods to inhibit endometr mythosis
AU701946B2 (en) Methods for bone healing and fracture repair
EP0771201B1 (en) Use of 2-phenyl-3-aroylbenzothiophenes for the preparation of a medicament for inhibiting primary endometrial hyperplasia
EP0729755A2 (en) 2-Phenyl-3-aroylbenziothiophenen for inhibiting ovarian cancer
US20040167170A1 (en) Methods of preventing breast cancer
AU2124097A (en) Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
MXPA97006520A (en) Methods to inhibit the ova cancer
EP0921799A1 (en) Methods of inhibiting colon tumors
CA2244112A1 (en) Methods of inhibiting colon tumors